Vertex Inc. (VERX)
Vertex: Profitability Ramps Up As Company Drives Efficiency Initiatives
Vertex remains a "Buy" as its tax compliance software business shows resilience amid broad SaaS sector weakness. Despite a ~20% YTD and 60% 1-year decline, VERX delivered a strong Q1 beat-and-raise, with accelerating growth and expanding margins. Fears of AI disruption are overblown for VERX, given the complexity and criticality of tax compliance, reinforcing its competitive moat.
Vertex, Inc. (VERX) Q1 2026 Earnings Call Transcript
Vertex, Inc. (VERX) Q1 2026 Earnings Call Transcript
Compared to Estimates, Vertex (VERX) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Vertex (VERX) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Vertex (VERX) Tops Q1 Earnings and Revenue Estimates
Vertex (VERX) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.15 per share a year ago.
Vertex tops profit estimates as sales of new cystic fibrosis drug surge
Vertex Pharmaceuticals on Monday beat Wall Street estimates for first-quarter adjusted profit, helped by a near eight-fold surge in sales of its new cystic fibrosis treatment.
Vertex Gears Up to Report Q1 Earnings: What Investors Can Expect
VRTX heads into Q1 earnings with Trikafta demand, rising Alyftrek sales, and Casgevy and Journavx sales in focus ahead of the May 4 report.
Vertex Pharmaceuticals: Looking For Signs Of Success In Q1 Earnings
Vertex Pharmaceuticals remains the leader in cystic fibrosis but is now executing a tangible diversification into pain, renal, and gene therapies. VRTX's CF franchise continues to grow via ALYFTREK's launch, geographic expansion, and penetration into younger and rare mutation populations, supporting robust revenue. New products JOURNAVX and CASGEVY are gaining traction, and the renal pipeline—especially povetacicept—could become a second franchise with multi-billion-dollar potential.
Vertex Pharmaceuticals: Label Expansions For ALYFTREK And TRIKAFTA Plus Strong Demand
Vertex Pharmaceuticals (VRTX) remains a "Strong Buy", driven by robust CF franchise growth and successful label expansions for ALYFTREK and TRIKAFTA. VRTX's new label expansions now cover 95% of U.S. CF patients, adding 800 eligible patients and supporting continued revenue growth. Positive phase 3 data for povetacicept in IgAN and ongoing regulatory submissions position VRTX for further diversification beyond CF.
Vertex Stock Falls 4.8% in a Month: Buying Opportunity or Red Flag?
VRTX stock slips nearly 5% as concerns over new drug uptake and pipeline setbacks weigh, even as its dominant CF franchise continues to drive steady growth.
Is Vertex Pharmaceuticals Heading to $600?
The biotech company is the leader in the cystic fibrosis market and is quickly expanding into other treatment areas. Vertex forecasts its newer medicines may add $500 million to revenue this year.
Vertex, Inc. (VERX) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript
Vertex, Inc. (VERX) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript
Vertex Pharmaceuticals Stock: Is The Bull Run Over (Rating Downgrade)
I believe Vertex Pharmaceuticals Incorporated's bull run has come to an end. There's a divergence between its stock price growth over the past 5 months and the performance of Journavx and the cystic fibrosis franchise. So, in Q4, Trikafta+Kaftrio sales declined 3.1% quarter-on-quarter to about $2.57 billion, missing my "base case" scenario by $45 million.
